BR112022015104A2 - Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição - Google Patents
Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composiçãoInfo
- Publication number
- BR112022015104A2 BR112022015104A2 BR112022015104A BR112022015104A BR112022015104A2 BR 112022015104 A2 BR112022015104 A2 BR 112022015104A2 BR 112022015104 A BR112022015104 A BR 112022015104A BR 112022015104 A BR112022015104 A BR 112022015104A BR 112022015104 A2 BR112022015104 A2 BR 112022015104A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- roflumilast
- life
- extend
- distribution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
MÉTODO PARA MELHORAR A DISTRIBUIÇÃO E ESTENDER A MEIA-VIDA PLASMÁTICA DE UMA COMPOSIÇÃO DE ROFLUMILASTE E USO DE UMA COMPOSIÇÃO. A presente invenção é direcionada a métodos para melhorar o resultado terapêutico do tratamento com roflumilaste. O resultado terapêutico é melhorado por meio da distribuição consistente e/ou uma meia-vida plasmática mais longa de uma composição de roflumilaste administrada por via tópica. A composição de roflumilaste inclui preferencialmente fosfato de dicetila, fosfato de ceteth-10, dietilenoglicol monoetil éter e/ou hexilenoglicol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/778,845 US11129818B2 (en) | 2017-06-07 | 2020-01-31 | Topical roflumilast formulation having improved delivery and plasma half life |
PCT/US2021/015740 WO2021155173A1 (en) | 2020-01-31 | 2021-01-29 | Topical roflumilast formulation having improved delivery and plasma half-life |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022015104A2 true BR112022015104A2 (pt) | 2022-09-27 |
Family
ID=74759470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022015104A BR112022015104A2 (pt) | 2020-01-31 | 2021-01-29 | Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4096630A1 (pt) |
JP (1) | JP2023513092A (pt) |
KR (1) | KR20220134617A (pt) |
CN (1) | CN115551478A (pt) |
AU (1) | AU2021214399A1 (pt) |
BR (1) | BR112022015104A2 (pt) |
CA (1) | CA3166300A1 (pt) |
IL (1) | IL295172A (pt) |
MX (1) | MX2022009399A (pt) |
WO (1) | WO2021155173A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240108609A1 (en) * | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100331255B1 (ko) | 1993-07-02 | 2002-10-25 | 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 | 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도 |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
CN101491520B (zh) | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
KR20210044191A (ko) * | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
-
2021
- 2021-01-29 MX MX2022009399A patent/MX2022009399A/es unknown
- 2021-01-29 IL IL295172A patent/IL295172A/en unknown
- 2021-01-29 CN CN202180017566.3A patent/CN115551478A/zh active Pending
- 2021-01-29 CA CA3166300A patent/CA3166300A1/en active Pending
- 2021-01-29 WO PCT/US2021/015740 patent/WO2021155173A1/en unknown
- 2021-01-29 AU AU2021214399A patent/AU2021214399A1/en active Pending
- 2021-01-29 KR KR1020227029999A patent/KR20220134617A/ko active Search and Examination
- 2021-01-29 BR BR112022015104A patent/BR112022015104A2/pt unknown
- 2021-01-29 EP EP21708433.4A patent/EP4096630A1/en active Pending
- 2021-01-29 JP JP2022546613A patent/JP2023513092A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL295172A (en) | 2022-09-01 |
CN115551478A (zh) | 2022-12-30 |
AU2021214399A1 (en) | 2022-08-25 |
CA3166300A1 (en) | 2021-08-05 |
JP2023513092A (ja) | 2023-03-30 |
KR20220134617A (ko) | 2022-10-05 |
WO2021155173A1 (en) | 2021-08-05 |
EP4096630A1 (en) | 2022-12-07 |
MX2022009399A (es) | 2022-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
BR112023015067A2 (pt) | Composto de quinazolina para induzir a degradação de proteína kras g12d mutante | |
MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
BR112022015104A2 (pt) | Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição | |
BR112023002453A2 (pt) | Composições de agente de via de estresse de replicação e métodos para tratar câncer | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
MX2023006370A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. | |
BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
CL2021001638A1 (es) | Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos | |
CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
EP4356966A3 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
BR112022026558A2 (pt) | Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo | |
JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
BR112023002883A2 (pt) | Conjunto de composições para tratamento bucal anticárie | |
WO2019241742A8 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |